Osiris Therapeutics, Inc., a stem cell company, focuses on developing and marketing products to treat serious medical conditions in wound, orthopedic, and sports medicine markets. The company’s Biosurgery products, including Grafix, Ovation, Cartiform, and OvationOS, each of which it developed and manufacture. Grafix is a three-dimensional placental tissue matrix for use as a wound covering for application directly to acute and chronic wounds, including diabetic foot ulcers, venous leg ulcers, and burns. OvationOS, a viable bone matrix, is the company’s newest product to be used for bone repair and regeneration. OvationOS is a functionally complete alternative to autograft, the gold standard in bone regeneration. The company markets and distributes Grafix directly to hospitals, clinics and physician offices primarily through its direct sales organization and with limited marketing through agents and distributors. The company distributes Cartiform and OvationOS. It markets its products directly to hospitals and through selected specialty distributors. A significant market for Grafix is chronic wounds, which are primarily treated in the outpatient setting. Strategy The three pillars of the company’s business strategy are to continue its history of innovation, bring about transformation, and to ensure differentiation of its company. Dispositions In 2013, the company sold its Therapeutics business to a wholly-owned subsidiary of Mesoblast Limited. Significant Events In December 2014, Osiris Therapeutics said it has entered into an exclusive, worldwide partnership with Stryker Corporation for the commercialization and development of OSIR's viable bone matrix tissue form. The agreement provides SYK with exclusive, worldwide rights to OSIR's viable bone matrix under the name BIO4. Regulations Grafix, OvationOS, and Cartiform are regulated by the United States Food and Drug Administration (FDA) under 21 CFR Part 1271 Part 361 of the Public Health Service Act, Human Cells, Tissues and Cellular and Tissue-based Products. The company is registered with the FDA as a tissue establishment and is accredited by the American Association of Tissue Banks. History Osiris Therapeutics, Inc. was founded in 1992 as a Delaware corporation. The company reincorporated as a Maryland corporation in 2010.
osiris therapeutics inc (OSIR:NASDAQ GM)
7015 Albert Einstein Drive
Columbia, MD 21046
|BioTime Inc||$5.22 USD||-0.21|
|Mesoblast Ltd||A$3.79 AUD||-0.04|
|Ocata Therapeutics Inc||$6.98 USD||-0.02|
|Organovo Holdings Inc||$4.56 USD||-0.16|
|Vitrolife AB||kr155.00 SEK||0.00|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact OSIRIS THERAPEUTICS INC, please visit www.osiristx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.